Revenue
2020
2021
2022
2023
2024
2025
CVRx, Inc. (CVRX)
Price$3.05Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $56.7M | $51.3M | $39.3M | $22.5M | $13.0M | $6.1M |
| Gross profit | $48.3M | $43.0M | $33.0M | $17.5M | $9.4M | $4.6M |
| Gross margin | 85.33% | 83.75% | 84.08% | 77.75% | 72.08% | 76.21% |
| Research & development | $11.1M | $11.1M | $11.6M | $10.0M | $7.5M | $6.4M |
| Operating expenses | $99.6M | $102.4M | $76.1M | $60.0M | $35.4M | $16.1M |
| Operating income | −$51.3M | −$59.5M | −$43.1M | −$42.5M | −$26.0M | −$11.5M |
| Operating margin | −90.49% | −115.98% | −109.69% | −189.27% | −199.20% | −190.22% |
| EBITDA | −$50.5M | −$58.9M | −$42.6M | −$42.1M | −$25.8M | −$11.4M |
| EBITDA margin | −89.16% | −114.78% | −108.36% | −187.44% | −197.91% | −188.98% |
| Net income | −$53.3M | −$60.0M | −$41.2M | −$41.4M | −$43.1M | −$14.1M |
| Net profit margin | −94.10% | −116.91% | −104.85% | −184.38% | −330.45% | −233.09% |
| Basic EPSper basic share | -$2.04 | -$2.65 | -$1.99 | -$2.02 | -$4.16 | -$37.01 |
| Diluted EPSper diluted share | -$2.04 | -$2.65 | -$1.99 | -$2.02 | -$4.16 | -$37.01 |
Owners
Reported shareholders
15.11%of listed shares
JOHNSON & JOHNSON4.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
JOHNSON & JOHNSON | 15.11%4.02M shares |
NEA Management Company, LLC | 7.34%1.95M shares |
Nielsen Kirk G. | ≈7.20%1.92M shares |
BlackRock, Inc. | 4.67%1.25M shares |
ROYAL BANK OF CANADA | 4.63%1.23M shares |
GSK plc | 3.78%1.01M shares |
Jain Mudit K. | ≈3.73%994.55K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.42%910.58K shares |
SILVERCREST ASSET MANAGEMENT GROUP LLC | 3.30%878.11K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.65%440.79K shares |
PFM Health Sciences, LP | 1.39%369.57K shares |
STATE STREET CORP | 1.38%366.35K shares |
Hykes Kevin | ≈1.07%284.24K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.86%230K shares |
UBS Group AG | 0.84%224.23K shares |
TUDOR INVESTMENT CORP ET AL | 0.77%205.68K shares |
GOLDMAN SACHS GROUP INC | 0.56%149.51K shares |
MORGAN STANLEY | 0.54%144.98K shares |
Kestra Advisory Services, LLC | 0.50%132.4K shares |
TWO SIGMA INVESTMENTS, LP | 0.50%132.4K shares |
Percentages use 26.64M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 2, 2026Form 4 · 10b5-1 | Adamson Philip B.Chief Medical Officer | SellCommon Stock | 1.3K | $7.90 | $10.0K | 61.6K |
| Mar 2, 2026Form 4 · 10b5-1 | John Robert AllenChief Revenue Officer | SellCommon Stock | 4.0K | $7.90 | $31.3K | 86.0K |
| Mar 2, 2026Form 4 · 10b5-1 | VERRASTRO PAULCHIEF MKTG & STRAT OFFICER | SellCommon Stock | 1.3K | $7.90 | $10.1K | 60.6K |
| Mar 2, 2026Form 4 · 10b5-1 | OASHEIM JAREDCHIEF FINANCIAL OFFICER | SellCommon Stock | 1.7K | $7.90 | $13.8K | 96.7K |
| Mar 2, 2026Form 4 · 10b5-1 | Hykes KevinPRES & CEO | SellCommon Stock | 7.8K | $7.90 | $61.3K | 284.2K |